Sheffield Medical Technologies Inc. deal

SHM (Houston) acquired from discoverer/owner Basil Hone an exclusive, worldwide license to Liposome-CD4 technology with the potential to complement SHM's Red Blood Cell-CD4 technology (RBC-CD4) as a tandem therapy for the treatment of HIV and AIDS.

Liposome-CD4 technology reconstitutes membrane CD4 in the lipid membrane of liposomes and encapsulates a cytotoxic agent. The complex will be targeted to the lymph nodes, whereas SHM's RBC-CD4 is designed to target HIV and HIV-infected cells in the blood. ...